SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

GANX

Gain Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 9h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor cash runway: at current burn rate (~$1M/month), the $11.7M cash provides roughly 12 months of runway. The Phase 2 start in Q1 2027 is the next major catalyst.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.08
T+0 close · Nov 10, 2026 · via day close
Latest settled
+2.78%
T+1 · $1.11
Vs SPY
+1.46%
α at T+1
Next horizon
T+5
due 10h ago
  1. T+0 · Nov 10 $1.08entry
  2. T+1 · 6d ago +2.78%α +1.46% · $1.11
  3. T+5 · due 10h ago Pending
  4. T+5 · todayOpen
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Gain Therapeutics reported Q3 2026 net loss of $0.07 per share, narrower than the $0.15 loss a year ago and better than the $-0.13 consensus. Cash burn continues with $11.7M on hand, and the company expects to start a Phase 2 trial of rexaceract in Q1 2027.

Key Financial Metrics

EPS
−$0.07
est −$0.13 · +46.1%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Net loss per share $0.07 for Q3 2026 vs $0.15 in Q3 2025
  • Cash and cash equivalents $11.7M as of Sep 30, 2026, down from $20.8M at Dec 31, 2025
  • Phase 2 trial of rexaceract expected to begin in Q1 2027
  • R&D expenses fell to $1.4M from $2.8M year-over-year
  • Weighted average shares outstanding 43.8M for Q3 2026 vs 35.0M a year ago

Financial Impact

Net loss per share $0.07 vs consensus $-0.13; cash burn $9.1M in 9 months

net losscash positionR&D spending

Risk Factors

  • Cash burn continues with no near-term revenue; may need to raise capital before Phase 2 completion
  • Phase 2 trial design and enrollment delays could push timeline
  • Pre-revenue clinical-stage biotech with no approved products

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3399309

Track record

15 reports on GANX

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +13.74% at T+60 after the May 26, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 17, 2026today Press Release Bullish 6/10 Entry $1.19 Now $1.18 −0.84% settles Nov 25
  2. Nov 10, 20267d ago Press Release Neutral 4/10 Viewing Entry $1.08 Now $1.18 +9.26% due Nov 17
  3. Oct 30, 202618d ago 3 Neutral 2/10 Entry $1.13 to $1.09 Now $1.18 +4.42% ▼ −3.54% −3.62% vs SPY
  4. Oct 28, 202620d ago 8-K Neutral 2/10 Entry $1.19 to $0.9604 Now $1.18 −0.84% ▼ −19.29% −14.57% vs SPY
  5. Oct 1, 20266w ago Press Release Neutral 4/10 Entry $1.72 to $1.62 Now $1.18 −31.40% ▼ −6.10% −7.41% vs SPY
  6. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $1.72 to $1.62 Now $1.18 −31.40% ▼ −6.10% −7.41% vs SPY
  7. Aug 11, 202614w ago Press Release Bullish 6/10 Entry $2.06 to $2.03 Now $1.18 −42.72% ▼ −1.46% −1.05% vs SPY
  8. Jul 16, 202617w ago 8-K Neutral 4/10 Entry $1.66 to $1.82 Now $1.18 −28.92% ▲ +9.64% +11.31% vs SPY
  9. Jun 29, 202620w ago 8-K Bullish 7/10 Entry $2.03 to $1.81 Now $1.18 −41.87% ▼ −10.84% −11.44% vs SPY
  10. Jun 29, 202620w ago Press Release Bullish 5/10 Entry $2.03 to $1.81 Now $1.18 −41.87% ▼ −10.84% −11.44% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (16h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026